tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Sep 2;10(9):1449.
doi: 10.3390/vaccines10091449.
Analysis of Adverse Effects of COVID-19 Vaccines Experienced by Healthcare Workers at Guizhou Provincial Staff Hospital, China
Yunhua Wei[SUP] 1 2 [/SUP], Yan Wang[SUP] 1 [/SUP], Lin Liu[SUP] 1 3 [/SUP], Yan Zha[SUP] 1 4 [/SUP], Yuqi Yang[SUP] 1 4 [/SUP], Yuanlin Wang[SUP] 1 5 [/SUP], Neil Roberts[SUP] 6 [/SUP], Yaying Li[SUP] 1 [/SUP]
Affiliations
Abstract
Objective: A retrospective survey was conducted of adverse events following immunization (AEFI) experienced by health care workers (HCWs) in a relatively remote ethnic region in southwest China (Guizhou Province) who received COVID-19 vaccines.
Methods: From 18 January 2021 to 21 January 2022, all HCWs of Guizhou Provincial Staff Hospital, China, who received at least one dose of inactivated COVID-19 vaccine (Vero cell), recombinant novel coronavirus vaccine (CHO cell), or one dose of adenovirus type-5 (Ad5) vectored COVID-19 vaccine were asked to complete a self-report questionnaire to provide information on any adverse events that may have occurred in the first 3 days after injection. The frequency of AEFI corresponding to the three types of vaccines were compared and the potential risks of AEFI due to the three different vaccines were predicted by multivariate logistic regression analysis.
Results: Of the 904 HCWs who completed the survey, the rates of AEFI were 10.1% (80/794) due to Vero cell, 16.3% (13/80) due to CHO cell, and 46.67% (14/30) due to Ad5 vectored vaccines, and the rates were significantly different (χ[SUP]2[/SUP] = 38.7, p < 001) between the three vaccines. Multivariate logistic regression models predict that (1) compared to the Ad 5 vectored group, the risk of AEFI occurrence in the Vero cell group was reduced by about 85.9% (OR = 0.141, 95% CI: 0.065-0.306, p < 0.001) and in the CHO cell group by about 72.1% (OR = 0.279, 95% CI: 0.107-0.723, p = 0.009), (2) the odds for women experiencing AEFI were about 2.1 (OR = 2.093, 95% CI: 1.171-3.742, p = 0.013) times as high as those of men, and (3) the risk of AEFI for HCWs with a Bachelor's degree or above was about 2.2 (OR = 2.237, 95% CI: 1.434-3.489, p = 0.001) times higher than in HCWs who do not have a Bachelor's degree.
Conclusions: 1. The inactivated COVID-19 vaccine (Vero cell), recombinant novel coronavirus vaccine (CHO cell), and adenovirus type-5 (Ad5) vectored COVID-19 vaccine made in China are safe and relatively broad-spectrum. 2. The prevalence of AEFI is more common in women healthcare workers. 3. The risk of AEFI was higher in those with a Bachelor's degree or above and may be related to the psychological and social effects triggered by the global COVID-19 pandemic.
Keywords: adenovirus type-5 (Ad5) vectored COVID-19 vaccine; adverse events following immunization; healthcare workers; inactivated COVID-19 vaccine (Vero cell); recombinant novel coronavirus vaccine (CHO cell).
. 2022 Sep 2;10(9):1449.
doi: 10.3390/vaccines10091449.
Analysis of Adverse Effects of COVID-19 Vaccines Experienced by Healthcare Workers at Guizhou Provincial Staff Hospital, China
Yunhua Wei[SUP] 1 2 [/SUP], Yan Wang[SUP] 1 [/SUP], Lin Liu[SUP] 1 3 [/SUP], Yan Zha[SUP] 1 4 [/SUP], Yuqi Yang[SUP] 1 4 [/SUP], Yuanlin Wang[SUP] 1 5 [/SUP], Neil Roberts[SUP] 6 [/SUP], Yaying Li[SUP] 1 [/SUP]
Affiliations
- PMID: 36146526
- DOI: 10.3390/vaccines10091449
Abstract
Objective: A retrospective survey was conducted of adverse events following immunization (AEFI) experienced by health care workers (HCWs) in a relatively remote ethnic region in southwest China (Guizhou Province) who received COVID-19 vaccines.
Methods: From 18 January 2021 to 21 January 2022, all HCWs of Guizhou Provincial Staff Hospital, China, who received at least one dose of inactivated COVID-19 vaccine (Vero cell), recombinant novel coronavirus vaccine (CHO cell), or one dose of adenovirus type-5 (Ad5) vectored COVID-19 vaccine were asked to complete a self-report questionnaire to provide information on any adverse events that may have occurred in the first 3 days after injection. The frequency of AEFI corresponding to the three types of vaccines were compared and the potential risks of AEFI due to the three different vaccines were predicted by multivariate logistic regression analysis.
Results: Of the 904 HCWs who completed the survey, the rates of AEFI were 10.1% (80/794) due to Vero cell, 16.3% (13/80) due to CHO cell, and 46.67% (14/30) due to Ad5 vectored vaccines, and the rates were significantly different (χ[SUP]2[/SUP] = 38.7, p < 001) between the three vaccines. Multivariate logistic regression models predict that (1) compared to the Ad 5 vectored group, the risk of AEFI occurrence in the Vero cell group was reduced by about 85.9% (OR = 0.141, 95% CI: 0.065-0.306, p < 0.001) and in the CHO cell group by about 72.1% (OR = 0.279, 95% CI: 0.107-0.723, p = 0.009), (2) the odds for women experiencing AEFI were about 2.1 (OR = 2.093, 95% CI: 1.171-3.742, p = 0.013) times as high as those of men, and (3) the risk of AEFI for HCWs with a Bachelor's degree or above was about 2.2 (OR = 2.237, 95% CI: 1.434-3.489, p = 0.001) times higher than in HCWs who do not have a Bachelor's degree.
Conclusions: 1. The inactivated COVID-19 vaccine (Vero cell), recombinant novel coronavirus vaccine (CHO cell), and adenovirus type-5 (Ad5) vectored COVID-19 vaccine made in China are safe and relatively broad-spectrum. 2. The prevalence of AEFI is more common in women healthcare workers. 3. The risk of AEFI was higher in those with a Bachelor's degree or above and may be related to the psychological and social effects triggered by the global COVID-19 pandemic.
Keywords: adenovirus type-5 (Ad5) vectored COVID-19 vaccine; adverse events following immunization; healthcare workers; inactivated COVID-19 vaccine (Vero cell); recombinant novel coronavirus vaccine (CHO cell).